[go: up one dir, main page]

MX2016012278A - Deteccion temprana de preeclampsia. - Google Patents

Deteccion temprana de preeclampsia.

Info

Publication number
MX2016012278A
MX2016012278A MX2016012278A MX2016012278A MX2016012278A MX 2016012278 A MX2016012278 A MX 2016012278A MX 2016012278 A MX2016012278 A MX 2016012278A MX 2016012278 A MX2016012278 A MX 2016012278A MX 2016012278 A MX2016012278 A MX 2016012278A
Authority
MX
Mexico
Prior art keywords
preclampsia
subject
preeclampsy
early
detection
Prior art date
Application number
MX2016012278A
Other languages
English (en)
Other versions
MX384485B (es
Inventor
Simon Carlos
GARRIDO Tamara
Pellicer Antonio
Original Assignee
Igenomix S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenomix S L filed Critical Igenomix S L
Publication of MX2016012278A publication Critical patent/MX2016012278A/es
Publication of MX384485B publication Critical patent/MX384485B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención proporciona ensayos no invasivos para identificar de manera confiable mujeres que tienen o están predispuestas a desarrollar preclampsia (PE); el método comprende medir un nivel de anexina A2 (ANXA2) en una muestra de prueba obtenida de un sujeto; e identificar al sujeto que tiene preclampsia o tiene un riesgo elevado de desarrollar preclampsia cuando el nivel de ANXA2 en la muestra de prueba disminuye con relación a una muestra de control; también se proporcionan métodos para tratar a un sujeto que se ha identificado que tiene PE o está en un riesgo elevado de desarrollar preclampsia.
MX2016012278A 2014-03-21 2015-03-19 Deteccion temprana de preeclampsia. MX384485B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968728P 2014-03-21 2014-03-21
US201461969520P 2014-03-24 2014-03-24
PCT/IB2015/001404 WO2015166353A2 (en) 2014-03-21 2015-03-19 Early detection of preeclampsia

Publications (2)

Publication Number Publication Date
MX2016012278A true MX2016012278A (es) 2017-04-27
MX384485B MX384485B (es) 2025-03-14

Family

ID=54147245

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012278A MX384485B (es) 2014-03-21 2015-03-19 Deteccion temprana de preeclampsia.

Country Status (8)

Country Link
US (1) US20170097358A1 (es)
EP (1) EP3120152A2 (es)
JP (1) JP6684263B2 (es)
CN (2) CN106662589B (es)
BR (1) BR112016021630A2 (es)
CA (1) CA2943284A1 (es)
MX (1) MX384485B (es)
WO (1) WO2015166353A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
SMT202400270T1 (it) 2014-06-17 2024-07-09 Asherman Therapy S L Terapia con cellule staminali in patologie endometriali
CA3074808A1 (en) * 2017-09-05 2019-03-14 Igenomix S.L. Methods and devices for detecting biomarkers associated with preeclampsia
US12146886B2 (en) 2018-03-06 2024-11-19 The Feinstein Institutes For Medical Research Methods for detecting and treating endometriosis
CN114990038B (zh) * 2022-05-24 2023-06-27 郑州大学 一种细菌外膜囊泡及其在制备先兆子痫治疗药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712103A (en) * 1995-02-13 1998-01-27 Regents Of The University Of California Diagnostic assay for the prediction of preeclampsia
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
CN101616927A (zh) * 2005-09-15 2009-12-30 迪爱麦有限公司 诊断先兆子痫的方法
WO2008134881A1 (en) * 2007-05-05 2008-11-13 The University Of Western Ontario Methods for the detection of preeclampsia
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
CN105403701B (zh) * 2008-04-11 2017-04-12 中国医学科学院肿瘤医院 膜联蛋白a2的血清检测方法、检测试剂盒及其应用
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
CN102483418B (zh) * 2008-10-31 2015-01-07 耶鲁大学 先兆子痫检测和治疗的方法和组合物
US20120107825A1 (en) * 2010-11-01 2012-05-03 Winger Edward E Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
KR20140106550A (ko) * 2011-11-30 2014-09-03 에이전시 포 사이언스, 테크놀로지 앤드 리서치 생물학적 모니터링을 위한 ｇｍ1 갱글리오사이드와 아넥신 ⅴ 마이크로입자 폴리펩타이드 비율
WO2014001244A1 (en) * 2012-06-27 2014-01-03 Roche Diagnostics Gmbh MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
CN103436552A (zh) * 2013-09-10 2013-12-11 浙江大学 一种人源annexin A2的生产方法及其应用

Also Published As

Publication number Publication date
CN110927385A (zh) 2020-03-27
EP3120152A2 (en) 2017-01-25
CA2943284A1 (en) 2015-11-05
WO2015166353A3 (en) 2016-01-21
CN106662589A (zh) 2017-05-10
CN106662589B (zh) 2019-07-30
US20170097358A1 (en) 2017-04-06
JP2017513021A (ja) 2017-05-25
BR112016021630A2 (pt) 2020-02-27
JP6684263B2 (ja) 2020-04-22
WO2015166353A2 (en) 2015-11-05
MX384485B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
CO2017006740A2 (es) Anticuerpos anti–cd79b
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
MX2016013261A (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX383381B (es) Métodos y composiciones para detectar proteínas mal plegadas.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
CL2016002419A1 (es) Métodos para determinar la probabilidad de padecer cáncer de próstata que comprende inmunoensayos de antígenos específicos de próstata
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
WO2016057702A3 (en) Methods for prognosing and preventing metastatic liver disease
MX2016012278A (es) Deteccion temprana de preeclampsia.
MX382446B (es) Métodos para la detección de apolipoproteínas.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2020002243A (es) Anticuerpos utiles en diagnosis de cancer.
BR112016017926A2 (pt) ensaio para detectar periostina humana
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
BR112017023473A2 (pt) método de detecção e quantificação de ácido nucleico e composições
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
MA40636A (fr) Procédés pour détecter le cancer de la prostate
MX2017010122A (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.